{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:19:43Z","timestamp":1776259183540,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T00:00:00Z","timestamp":1437609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s40265-015-0441-7","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T09:51:03Z","timestamp":1437558663000},"page":"1405-1412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Collagenase Clostridium Histolyticum: A Review in Peyronie\u2019s Disease"],"prefix":"10.1007","volume":"75","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,23]]},"reference":[{"issue":"5","key":"441_CR1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/1389450115666141114163128","volume":"16","author":"A Alwaal","year":"2014","unstructured":"Alwaal A, Hussein AA, Zaid UB, et al. Management of Peyronie\u2019s Disease after Collagenase (Xiaflex\u00ae). Curr Drug Targets. 2014;16(5):484\u201394.","journal-title":"Curr Drug Targets."},{"issue":"5","key":"441_CR2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1756287214537331","volume":"6","author":"MA Egui Rojo","year":"2014","unstructured":"Egui Rojo MA, Moncada Iribarren I, Carballido Rodriguez J, et al. Experience in the use of Collagenase Clostridium Histolyticum in the management of Peyronie\u2019s disease: current data and future prospects. Ther Adv Urol. 2014;6(5):192\u20137.","journal-title":"Ther Adv Urol."},{"issue":"5","key":"441_CR3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.ijir.3900875","volume":"14","author":"RB Moreland","year":"2002","unstructured":"Moreland RB, Nehra A. Pathophysiology of Peyronie\u2019s disease. Int J Impot Res. 2002;14(5):406\u201310.","journal-title":"Int J Impot Res."},{"issue":"8","key":"441_CR4","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/j.1743-6109.2008.00883.x","volume":"5","author":"R Rosen","year":"2008","unstructured":"Rosen R, Catania J, Lue T, et al. Impact of Peyronie\u2019s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5(8):1977\u201384.","journal-title":"J Sex Med."},{"issue":"9","key":"441_CR5","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/j.1743-6109.2008.00949.x","volume":"5","author":"JF Smith","year":"2008","unstructured":"Smith JF, Walsh TJ, Conti SL, et al. Risk factors for emotional and relationship problems in Peyronie\u2019s disease. J Sex Med. 2008;5(9):2179\u201384.","journal-title":"J Sex Med."},{"issue":"8","key":"441_CR6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","volume":"5","author":"CJ Nelson","year":"2008","unstructured":"Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie\u2019s disease. J Sex Med. 2008;5(8):1985\u201390.","journal-title":"J Sex Med."},{"issue":"12","key":"441_CR7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11934-014-0459-5","volume":"15","author":"BA Sherer","year":"2014","unstructured":"Sherer BA, Warrior K, Levine LA. 2013\u20132014 updates in Peyronie\u2019s disease management. Curr Urol Rep [Electronic Resource]. 2014;15(12):459.","journal-title":"Curr Urol Rep [Electronic Resource]."},{"issue":"2","key":"441_CR8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajur.2015.04.019","volume":"2","author":"AA Hussein","year":"2015","unstructured":"Hussein AA, Alwaal A, Lue T. All about Peyronie\u2019s disease. Asian J Urol. 2015;2(2):70\u20138.","journal-title":"Asian J Urol."},{"issue":"3","key":"441_CR9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","volume":"62","author":"K Hatzimouratidis","year":"2012","unstructured":"Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543\u201352.","journal-title":"Eur Urol."},{"key":"441_CR10","unstructured":"Glenwood GmBH. Overview of Glenwood preparations. 2015. http:\/\/glenwood.de\/ . Accessed 26 June 2015."},{"key":"441_CR11","unstructured":"Auxilium Pharmaceuticals Inc. Xiaflex (Collagenase Clostridium Histolyticum): US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/ . Accessed 29 June 2015."},{"key":"441_CR12","unstructured":"European Medicines Agency. Xiapex (Collagenase Clostridium Histolyticum): summary of product sharacteristics. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 29 June 2015."},{"key":"441_CR13","doi-asserted-by":"crossref","unstructured":"Levine LA, Schmid TM, Emeigh Hart SG, et al. Collagenase Clostridium Histolyticum degrades type I and III collagen while sparing type IV collagen in vitro in Peyronie\u2019s plaque explants [abstract no. PD22-03 plus oral presentation]. In: American Urological Association Annual Meeting. 2014.","DOI":"10.1016\/j.juro.2014.02.1854"},{"issue":"3","key":"441_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","volume":"10","author":"MK Gelbard","year":"1982","unstructured":"Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie\u2019s disease experimental studies. Urol Res. 1982;10(3):135\u201340.","journal-title":"Urol Res."},{"issue":"4 Suppl","key":"441_CR15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0022-5347(09)60794-1","volume":"181","author":"M Carlo Del","year":"2009","unstructured":"Del Carlo M, Cole AA, Emeigh Hart SG, et al. Comparative analaysis of collagen degradation in Peyronie\u2019s disease plaque and Dupuytren\u2019s contracture cord tissue injected with mixed collagenase subtypes [abstract no. 780]. J Urol. 2009;181(4 Suppl):279.","journal-title":"J Urol."},{"issue":"2","key":"441_CR16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-5347(17)47123-0","volume":"134","author":"MK Gelbard","year":"1985","unstructured":"Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie\u2019s disease. J Urol. 1985;134(2):280\u20133.","journal-title":"J Urol."},{"issue":"1","key":"441_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study. J Urol. 1993;149(1):56\u20138.","journal-title":"J Urol."},{"issue":"1","key":"441_CR18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","volume":"5","author":"GH Jordan","year":"2008","unstructured":"Jordan GH. The use of intralesional Clostridial collagenase injection therapy for Peyronie\u2019s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5(1):180\u20137.","journal-title":"J Sex Med."},{"issue":"6","key":"441_CR19","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of Collagenase Clostridium Histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268\u201374.","journal-title":"J Urol."},{"issue":"1","key":"441_CR20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of Collagenase Clostridium Histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248\u201358.","journal-title":"J Sex Med."},{"issue":"1","key":"441_CR21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of Collagenase Clostridium Histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199\u2013207.","journal-title":"J Urol."},{"issue":"11","key":"441_CR22","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1111\/jsm.12312","volume":"10","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Hellstrom WJ, McMahon CG, et al. Baseline characteristics from an ongoing phase 3 study of Collagenase Clostridium Histolyticum in patients with Peyronie\u2019s disease. J Sex Med. 2013;10(11):2822\u201331.","journal-title":"J Sex Med."},{"key":"441_CR23","doi-asserted-by":"crossref","unstructured":"McMahon C, Auerbach S, Liu G, et al. Curvature deformity and symptom bother improvement over time in patients with Peyronie\u2019s disease treated with Collagenase Clostridium Histolyticum [abstract no. 1661]. In: 108th Annual Meeting of the American Urological Association. 2013.","DOI":"10.1016\/j.juro.2013.02.3075"},{"key":"441_CR24","unstructured":"European Medicines Agency. Assessment report (Xiapex). 2014. http:\/\/www.ema.europa.eu\/ . Accessed 26 June 2015."},{"issue":"2","key":"441_CR25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","volume":"190","author":"WJ Hellstrom","year":"2013","unstructured":"Hellstrom WJ, Feldman R, Rosen RC, et al. Bother and distress associated with Peyronie\u2019s disease: validation of the Peyronie\u2019s disease questionnaire. J Urol. 2013;190(2):627\u201334.","journal-title":"J Urol."},{"issue":"4","key":"441_CR26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/jsm.12838","volume":"12","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Currie BM, Thompson CL, et al. Responsiveness of the Peyronie\u2019s Disease Questionnaire (PDQ). J Sex Med. 2015;12(4):1072\u20139.","journal-title":"J Sex Med."},{"key":"441_CR27","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of Collagenase Clostridium Histolyticum in the treatment of Peyronie\u2019s disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase 3 studies. BJU Int. 2015. doi: 10.1111\/bju.13096 .","journal-title":"BJU Int."},{"key":"441_CR28","doi-asserted-by":"crossref","unstructured":"Lipshultz LI, Sadeghi-Nejad H, Mills J, et al. Peyronie\u2019s disease symptom bother reduction is related to penile curvature improvement in response to treatment with Collagenase Clostridium Histolyticum: results from two large double-blind, randomized, placebo-controlled phase 3 studies [abstract no. 075]. In: 20th Annual Fall Scientific Meeting of SMSNA. 2014.","DOI":"10.1016\/S1569-9056(15)60136-1"},{"key":"441_CR29","unstructured":"Goldstein I, Knoll D, Lipshultz LI, et al. Changes in the effects of Peyronie\u2019s disease after treatment with Collagenase Clostridium Histolyticum according to men with Peyronie\u2019s disease and their female sexual partners [abstract no. 064]. In: 20th Annual Fall Scientific Meeting of SMSNA. 2014."},{"key":"441_CR30","author":"CC Carson","year":"2015","unstructured":"Carson CC, Sadeghi-Nejad H, Tursi JP, et al. Analysis of the clinical safety of intralesional injection of Collagenase Clostridium Histolyticum for adults with Peyronie\u2019s disease. BJU Int. 2015. doi: 10.1111\/bju.13120 .","journal-title":"BJU Int."},{"key":"441_CR31","unstructured":"American Urological Association. Peyronie\u2019s disease: AUA guideline. 2015. https:\/\/www.auanet.org\/education\/guidelines\/peyronies-disease.cfm . Accessed 26 June 2015."},{"issue":"1","key":"441_CR32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jsm.12721","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Larsen SM. Surgical correction of persistent Peyronie\u2019s disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015;12(1):259\u201364.","journal-title":"J Sex Med."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0441-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0441-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0441-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T15:43:50Z","timestamp":1567007030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0441-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,23]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0441-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,23]]}}}